Stearic acid Clinical Trials

Size	Price	Qty
25mg	USD 147
1g	USD 970

Clinical Trials

Multiple clinical trials evaluate the metabolic and cardiovascular effects of stearic acid and related dietary lipids, focusing on conditions such as cardiometabolic health, dyslipidemia, cardiovascular disease risk, metabolic syndrome, and idiopathic triglyceride deposit cardiomyovasculopathy. Supported predominantly by academic institutions, medical centers, and agricultural research organizations, these studies encompass non-phased dietary interventions alongside early Phase 1/Phase 2 trials. Across these protocols, recruitment statuses range from completed studies to those currently listed as unknown or not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07766915	NOT_YET_RECRUITING	CVD Risk	Tufts University	2026-09
NCT04418102	COMPLETED	Cardiometabolic Health	King's College London	2020-02-01
NCT04053569	Unknown status	Metabolic Syndrome Protection Against	Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis	2019-10-01	Not Applicable
NCT04832217	Completed	Body Weight Changes\|Habits Diet\|Habit Food\|Life Change Events	Universidad de Zaragoza	2019-01-20	Not Applicable
NCT02835651	COMPLETED	Dyslipidemia	Maastricht University Medical Center	2016-04-14
NCT02502578	Completed	Idiopathic Triglyceride Deposit Cardiomyovasculopathy	Osaka University	2015-09	Phase 1\|Phase 2
NCT01428960	COMPLETED	Healthy	Malaysia Palm Oil Board	2011-06

(data from https://clinicaltrials.gov, updated on 2026-08-17)

Check the Stearic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Stearic acid is a long-chain saturated fatty acid that incorporates into cellular membranes and metabolic lipid pools, influencing membrane fluidity, lipid raft architecture, and intracellular signaling cascades involved in lipid oxidation and triglyceride synthesis. By modulating hepatic lipid processing and circulating lipoprotein metabolism, its administration impacts postprandial lipemia and lipid profiles, which is directly relevant to clinical evaluations targeting dyslipidemia, cardiometabolic health, and cardiovascular disease risk.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).